宿主导向疗法：对抗新冠病毒病的一种潜在解决方案。
Host-directed therapies: a potential solution to combat COVID-19.
作者信息
Baindara Piyush, Agrawal Sonali, Mandal Santi M
机构信息
Department of Molecular Microbiology and Immunology, University of Missouri , Columbia, MO, USA.
Immunology Division, ICMR-National JALMA Institute for Leprosy and Other Mycobacterial Diseases , Agra, India.
出版信息
Expert Opin Biol Ther. 2020 Oct;20(10):1117-1120. doi: 10.1080/14712598.2020.1807001. Epub 2020 Aug 12.
Abstract
Coronavirus disease 2019 (COVID-19) characterized by immuno-pathological host responses including pneumonia, lymphopenia, and cytokine storm that leads to severe lung inflammation, developed in acute respiratory distress syndrome (ARDS). In the absence of an effective vaccine or any definitive cure, the use of host-directed therapies is an effective alternative and demanding treatment option in the current pandemic outbreak of COVID-19.
摘要
2019冠状病毒病（COVID-19）的特征是免疫病理宿主反应，包括肺炎、淋巴细胞减少和细胞因子风暴，这些反应会导致严重的肺部炎症，并发展为急性呼吸窘迫综合征（ARDS）。在缺乏有效疫苗或明确治愈方法的情况下，使用宿主导向疗法是当前COVID-19大流行爆发中一种有效的替代和急需的治疗选择。
相似文献
1
Host-directed therapies: a potential solution to combat COVID-19.宿主导向疗法：对抗新冠病毒病的一种潜在解决方案。
Expert Opin Biol Ther. 2020 Oct;20(10):1117-1120. doi: 10.1080/14712598.2020.1807001. Epub 2020 Aug 12.
2
Lymphopenia in COVID-19: Therapeutic opportunities.新型冠状病毒肺炎中的淋巴细胞减少症：治疗机会。
Cell Biol Int. 2020 Sep;44(9):1792-1797. doi: 10.1002/cbin.11403. Epub 2020 Jun 3.
3
SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.新型冠状病毒炎症综合征。临床特征及免疫治疗的原理。
Int J Mol Sci. 2020 May 10;21(9):3377. doi: 10.3390/ijms21093377.
4
Respiratory and ventilator management of COVID-19.新型冠状病毒肺炎的呼吸与通气管理
J Pak Med Assoc. 2020 May;70(Suppl 3)(5):S60-S63. doi: 10.5455/JPMA.23.
5
Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.托珠单抗治疗 COVID-19 急性呼吸窘迫综合征：两例危重症患者的成功转归。
Immunotherapy. 2020 Oct;12(15):1127-1132. doi: 10.2217/imt-2020-0154. Epub 2020 Jul 14.
6
Cell-Free Therapies: Novel Approaches for COVID-19.无细胞疗法：治疗新冠肺炎的新方法。
Front Immunol. 2020 Sep 18;11:583017. doi: 10.3389/fimmu.2020.583017. eCollection 2020.
7
SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.SARS-CoV-2 感染免疫功能低下患者：体液免疫与细胞免疫。
J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000862.
8
Immunomodulation and Regeneration Properties of Dental Pulp Stem Cells: A Potential Therapy to Treat Coronavirus Disease 2019.牙髓干细胞的免疫调节和再生特性：一种治疗 2019 年冠状病毒病的潜在疗法。
Cell Transplant. 2020 Jan-Dec;29:963689720952089. doi: 10.1177/0963689720952089.
9
COVID-19 and the newly rediscovered multidisciplinarity.新冠疫情与新发现的多学科交叉性
Immunotherapy. 2020 Oct;12(15):1101-1103. doi: 10.2217/imt-2020-0205. Epub 2020 Sep 21.
10
Successful recovery of severe COVID-19 with cytokine storm treating with extracorporeal blood purification.COVID-19 患者经体外血液净化治疗后，细胞因子风暴得到成功控制，病情得到恢复。
Int J Infect Dis. 2020 Jul;96:618-620. doi: 10.1016/j.ijid.2020.05.065. Epub 2020 May 26.
引用本文的文献
1
Evolution of Antiviral Drug Resistance in SARS-CoV-2.新型冠状病毒（SARS-CoV-2）中抗病毒药物耐药性的演变
Viruses. 2025 May 18;17(5):722. doi: 10.3390/v17050722.
2
Differential Regulation of TFEB-Induced Autophagy during Mtb Infection and Starvation.结核分枝杆菌感染和饥饿期间TFEB诱导的自噬的差异调节
Microorganisms. 2023 Dec 8;11(12):2944. doi: 10.3390/microorganisms11122944.
3
Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19.间充质干细胞治疗 COVID-19 的临床试验。
Curr Stem Cell Res Ther. 2024;19(8):1055-1071. doi: 10.2174/011574888X260032230925052240.
4
Preventing Respiratory Viral Diseases with Antimicrobial Peptide Master Regulators in the Lung Airway Habitat.利用肺气道微环境中的抗菌肽主调控因子预防呼吸道病毒性疾病
Clin Pract. 2023 Jan 16;13(1):125-147. doi: 10.3390/clinpract13010012.
5
The metabolomics of a protein kinase C delta (PKCδ) knock-out mouse model.蛋白激酶 C 德尔塔（PKCδ）敲除小鼠模型的代谢组学。
Metabolomics. 2022 Nov 13;18(11):92. doi: 10.1007/s11306-022-01949-w.
6
Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2-A Candidate for Passive Immunization against COVID-19.鸡卵黄抗体（IgY）抗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）受体结合域（RBD）刺突蛋白用于COVID-19被动免疫的临床前评估。
Vaccines (Basel). 2022 Jan 17;10(1):128. doi: 10.3390/vaccines10010128.
7
Antiviral strategies targeting host factors and mechanisms obliging +ssRNA viral pathogens.针对宿主因子和机制的抗病毒策略，这些宿主因子和机制有利于 +ssRNA 病毒病原体。
Bioorg Med Chem. 2021 Sep 15;46:116356. doi: 10.1016/j.bmc.2021.116356. Epub 2021 Aug 8.
8
Increased sTREM-1 plasma concentrations are associated with poor clinical outcomes in patients with COVID-19.血清可溶性髓系细胞触发受体-1 水平升高与 COVID-19 患者临床预后不良相关。
Biosci Rep. 2021 Jul 30;41(7). doi: 10.1042/BSR20210940.
9
Crystal structure of SARS-CoV-2 Orf9b in complex with human TOM70 suggests unusual virus-host interactions.SARS-CoV-2 Orf9b 与人类 TOM70 复合物的晶体结构表明了不寻常的病毒-宿主相互作用。
Nat Commun. 2021 May 14;12(1):2843. doi: 10.1038/s41467-021-23118-8.
本文引用的文献
1
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.严重 COVID-19 患者的 I 型干扰素活性和炎症反应受损。
Science. 2020 Aug 7;369(6504):718-724. doi: 10.1126/science.abc6027. Epub 2020 Jul 13.
2
Coronavirus Disease 2019-COVID-19.新型冠状病毒肺炎。
Clin Microbiol Rev. 2020 Jun 24;33(4). doi: 10.1128/CMR.00028-20. Print 2020 Sep 16.
3
An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies.SARS-CoV-2/COVID-19 的最新进展，特别参考其临床病理学、发病机制、免疫病理学和缓解策略。
Travel Med Infect Dis. 2020 Sep-Oct;37:101755. doi: 10.1016/j.tmaid.2020.101755. Epub 2020 May 30.
4
COVID-19 update: Covid-19-associated coagulopathy.新型冠状病毒肺炎最新情况：新型冠状病毒肺炎相关凝血病
J Thromb Thrombolysis. 2020 Jul;50(1):54-67. doi: 10.1007/s11239-020-02134-3.
5
Effective treatment of severe COVID-19 patients with tocilizumab.托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
6
SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）进入因子与固有免疫基因一起在鼻上皮细胞中高表达。
Nat Med. 2020 May;26(5):681-687. doi: 10.1038/s41591-020-0868-6. Epub 2020 Apr 23.
7
COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET).新型冠状病毒肺炎与止血：来自意大利血栓形成与止血协会（SISET）的立场文件。
Blood Transfus. 2020 May;18(3):167-169. doi: 10.2450/2020.0083-20. Epub 2020 Apr 8.
8
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.迫切需要开展针对新型冠状病毒肺炎的抗肿瘤坏死因子疗法试验。
Lancet. 2020 May 2;395(10234):1407-1409. doi: 10.1016/S0140-6736(20)30858-8. Epub 2020 Apr 9.
9
Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19.SARS-CoV-2 和 SARS-CoV 在人肺中的比较复制和免疫激活特征：一项具有 COVID-19 发病机制意义的离体研究。
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409. doi: 10.1093/cid/ciaa410.
10
Pathogenesis of COVID-19 from a cell biology perspective.从细胞生物学角度看 COVID-19 的发病机制。
Eur Respir J. 2020 Apr 16;55(4). doi: 10.1183/13993003.00607-2020. Print 2020 Apr.
Zotero 插件